SYMJEPI®
(epinephrine) Injection

Indication

SYMJEPI® (epinephrine) Injection is indicated for the emergency treatment of allergic reactions (Type 1- including anaphylaxis) to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis.

SYMJEPI 0.15mg is intended for immediate administration in patients who weigh 33 to 66 pounds; SYMJEPI 0.3mg is intended for immediate administration in patients who weigh 66 pounds or more and who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.

SYMJEPI Resources

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.

Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit https://dmkpharma.com/

Check this page for the most recent updates regarding the merger process.